193 related articles for article (PubMed ID: 26877616)
1. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.
Broder MS; Chang E; Romanus D; Cherepanov D; Neary MP
World J Gastroenterol; 2016 Feb; 22(6):2118-25. PubMed ID: 26877616
[TBL] [Abstract][Full Text] [Related]
2. Direct costs of carcinoid syndrome diarrhea among adults in the United States.
Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
World J Gastroenterol; 2019 Dec; 25(47):6857-6865. PubMed ID: 31885426
[TBL] [Abstract][Full Text] [Related]
3. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
5. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
7. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
8. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.
Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Gomez MJ; Del Olmo-García MI; Lorenzo I; Díaz JÁ; Canal N; De la Cruz G; Villabona C
Clin Transl Oncol; 2021 Oct; 23(10):2046-2056. PubMed ID: 34109562
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
10. Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Med Econ; 2017 Apr; 20(4):353-362. PubMed ID: 27919177
[TBL] [Abstract][Full Text] [Related]
11. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
12. Resource utilization and costs of treating severe rotavirus diarrhea in young Mexican children from the health care provider perspective.
Granados-García V; Velázquez-Castillo R; Garduño-Espinosa J; Torres-López J; Muñoz-Hernández O
Rev Invest Clin; 2009; 61(1):18-25. PubMed ID: 19507471
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and expenditures in patients with atrial fibrillation treated with catheter ablation.
Ladapo JA; David G; Gunnarsson CL; Hao SC; White SA; March JL; Reynolds MR
J Cardiovasc Electrophysiol; 2012 Jan; 23(1):1-8. PubMed ID: 21777324
[TBL] [Abstract][Full Text] [Related]
14. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea.
Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):507-511. PubMed ID: 31448649
[No Abstract] [Full Text] [Related]
15. Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion need.
Goldberg SL; Chen E; Sasane M; Paley C; Guo A; Laouri M
Transfusion; 2012 Oct; 52(10):2131-8. PubMed ID: 22486790
[TBL] [Abstract][Full Text] [Related]
16. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
[TBL] [Abstract][Full Text] [Related]
17. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
18. Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine.
Silberstein SD; Lee L; Gandhi K; Fitzgerald T; Bell J; Cohen JM
Headache; 2018 Nov; 58(10):1579-1592. PubMed ID: 30375650
[TBL] [Abstract][Full Text] [Related]
19. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection.
Tencer T; Friedman HS; Li-McLeod J; Johnson K
J Manag Care Pharm; 2007; 13(9):790-8. PubMed ID: 18062730
[TBL] [Abstract][Full Text] [Related]
20. Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting.
Sabale U; Bodegård J; Sundström J; Östgren CJ; Nilsson P; Johansson G; Svennblad B; Henriksson M
Prim Care Diabetes; 2015 Oct; 9(5):330-7. PubMed ID: 25631469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]